{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T01:51:18Z","timestamp":1791510678388,"version":"4.3.4"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T00:00:00Z","timestamp":1747094400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Hematol Oncol"],"DOI":"10.1186\/s13045-025-01711-4","type":"journal-article","created":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:49:25Z","timestamp":1747147765000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Practice-changing updates on multiple myeloma: highlights from the 2024 ASH annual meeting"],"prefix":"10.1186","volume":"18","author":[{"given":"Ioannis","family":"Ntanasis-Stathopoulos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Panagiotis","family":"Malandrakis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"Gavriatopoulou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,13]]},"reference":[{"key":"1711_CR1","unstructured":"Dimopoulos MA, Voorhees PM, Schjesvold F et al. Daratumumab or active monitoring for High-Risk smoldering multiple myeloma. N Engl J Med 2024."},{"key":"1711_CR2","doi-asserted-by":"crossref","unstructured":"Terpos E, Malandrakis P, Ntanasis-Stathopoulos I et al. Sustained bone marrow and imaging MRD negativity for 3 years drives discontinuation of maintenance post ASCT in myeloma. Blood. 2025.","DOI":"10.1182\/blood.2024027686"},{"key":"1711_CR3","unstructured":"Mai EK, Bertsch U, Pozek E et al. Isatuximab, Lenalidomide, bortezomib, and dexamethasone induction therapy for Transplant-Eligible newly diagnosed multiple myeloma: final part 1 analysis of the GMMG-HD7 trial. J Clin Oncol 2024; JCO2402266."},{"key":"1711_CR4","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1182\/blood-2024-200871","volume":"144","author":"S Zweegman","year":"2024","unstructured":"Zweegman S, Facon T, Hungria V, et al. Phase 3 randomized study of daratumumab (DARA)\u2009+\u2009Bortezomib, Lenalidomide and dexamethasone (VRd) versus alone in patients with transplant-Ineligible newly diagnosed multiple myeloma or for whom transplant is not planned as initial therapy: analysis of minimal residual disease in the Cepheus trial. Blood. 2024;144:362\u2013362.","journal-title":"Blood"},{"key":"1711_CR5","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1182\/blood-2024-200336","volume":"144","author":"V Hungria","year":"2024","unstructured":"Hungria V, Robak P, Hus M, et al. Belantamab Mafodotin, bortezomib, and dexamethasone vs daratumumab, bortezomib, and dexamethasone in relapsed\/refractory multiple myeloma: overall survival analysis and updated efficacy outcomes of the phase 3 Dreamm-7 trial. Blood. 2024;144:772\u2013772.","journal-title":"Blood"},{"key":"1711_CR6","doi-asserted-by":"publisher","first-page":"4731","DOI":"10.1182\/blood-2024-199282","volume":"144","author":"M Beksac","year":"2024","unstructured":"Beksac M, Gonzalez Garcia E, Delimpasi S, et al. Belantamab Mafodotin plus Pomalidomide and dexamethasone vs Pomalidomide plus bortezomib and dexamethasone in patients with relapsed\/refractory multiple myeloma: A subset analysis in patients who have received 1 prior line of therapy including Lenalidomide. Blood. 2024;144:4731\u20134731.","journal-title":"Blood"},{"key":"1711_CR7","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1182\/blood-2024-212135","volume":"144","author":"J Gustine","year":"2024","unstructured":"Gustine J, Cirstea D, Branagan AR, et al. Previous HDM\/ASCT adversely impacts PFS with BCMA-Directed CAR T-Cell therapy in multiple myeloma. Blood. 2024;144:79\u201379.","journal-title":"Blood"},{"key":"1711_CR8","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1182\/blood-2024-202017","volume":"144","author":"B Dhakal","year":"2024","unstructured":"Dhakal B, Akhtar OS, Cowan AJ, et al. Talquetamab bridging: paving the way to B-Cell maturation antigen (BCMA) CAR-T cell therapy in relapsed\/refractory multiple myeloma (RRMM). Blood. 2024;144:931\u2013931.","journal-title":"Blood"},{"key":"1711_CR9","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1182\/blood-2024-199615","volume":"144","author":"R Banerjee","year":"2024","unstructured":"Banerjee R, Fritz AR, Akhtar OS, et al. 24-Hour urine testing does not add value to multiple myeloma response assessments: A secondary analysis of BMT CTN 0702. Blood. 2024;144:81\u201381.","journal-title":"Blood"},{"key":"1711_CR10","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1182\/blood-2024-202098","volume":"144","author":"J-S Claveau","year":"2024","unstructured":"Claveau J-S, Dispenzieri A, Kapoor P, et al. Eliminating the need for sequential confirmation of response in multiple myeloma. Blood. 2024;144:83\u201383.","journal-title":"Blood"}],"container-title":["Journal of Hematology & Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01711-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13045-025-01711-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13045-025-01711-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,13]],"date-time":"2025-05-13T14:49:32Z","timestamp":1747147772000},"score":1,"resource":{"primary":{"URL":"https:\/\/jhoonline.biomedcentral.com\/articles\/10.1186\/s13045-025-01711-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,13]]},"references-count":10,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1711"],"URL":"https:\/\/doi.org\/10.1186\/s13045-025-01711-4","relation":{},"ISSN":["1756-8722"],"issn-type":[{"value":"1756-8722","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,13]]},"assertion":[{"value":"25 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 May 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"INS declares honoraria from Janssen. PM declares honoraria from Janssen. MG declares honoraria from GSK, Janssen, Sanofi, Abbvie, Amgen, and Takeda.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"54"}}